Table 3. Characteristics of analgesia and side effect.
R25 (n = 23) | MR (n = 25) | R375 (n = 22) | P value | |
---|---|---|---|---|
Number requiring rescue analgesic: N | 21/23 | 20/25 | 19/22 | 0.532 |
Consumption of tramadol(0-24h) | 50[50,100] | 50[0,50] * | 50[50,50] * | 0.000 |
Consumption of tramadol(0-48h) | 100[50,100] | 50[50,75] * | 100[50,100] | 0.000 |
AUC-rest (0-24h) cm.h | 57.7±9.1 | 55.4±9.9 | 57.5±8.2 | 0.000 |
AUC-rest (0-48h) cm.h | 133.6±16.4 | 129.5±18.1 | 132.1±17.6 | 0.001 |
AUC-evoked (0-24h) cm.h | 96.6±12.6 | 85.2±9.0 * | 77.7±10.8 * | 0.000 |
AUC-evoked (0-48h) cm.h | 206.7±25.4 | 192.4±21.5 | 191.2±24.7 | 0.000 |
NRS in worst pain state | 5.30±0.6 | 4.80±0.5† | 5.32±0.6 | 0.000 |
Satisfaction score | 68.83±3.4 | 86.44±2.9* | 82.81±2.7* | 0.000 |
Side effect: N | ||||
Shivering | 1/23 | 0/25 | 0/22 | 0.355 |
Nausea | 4/23 | 5/25 | 3/22 | 0.846 |
Data were expressed as mean ± SD, median [interquartile ranges], or number of the patients (N).
R25: Perineural 0.25% ropivacaine with 15ml volume; MR: Perineural 200mg MgSO4 plus 0.25% ropivacaine with 15ml volume; R375: Perineural 0.375% ropivacaine with 15ml volume.
* P<0.01 indicates a significant difference in comparison to Group R25.
† P<0.05 indicates a significant difference in comparison to Group R25 and Group R375.